Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA neoantigen tumor vaccine (Shen Lin)
- Development stage
- Unknown
- Lead developer
- Everest Medicines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an investigator-initiated, personalized mRNA-based cancer vaccine developed for the treatment of advanced gastric cancer. Led by Dr. Shen Lin at Peking University Cancer Hospital, the vaccine utilizes messenger RNA technology to encode patient-specific tumor neoantigens—unique protein fragments derived from somatic mutations identified within an individual's tumor. By delivering these mRNA sequences, the vaccine aims to prime and expand the patient's own T-cell repertoire to recognize and eliminate cancer cells expressing these specific neoantigens. The vaccine is being evaluated in clinical trials both as a monotherapy and in combination with PD-1/L1 checkpoint inhibitors to enhance anti-tumor immune responses in patients who have failed standard treatments.
- Other names
- personalized mRNA neoantigen vaccineneoantigen tumor vaccinemRNA neoantigen tumor vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on mRNA neoantigen tumor vaccine (Shen Lin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA neoantigen tumor vaccine (Shen Lin).